Correction to: CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease (Bone Marrow Transplantation, (2022), 57, 10, (1592-1594), 10.1038/s41409-022-01749-9)

In the online version of article we state “Following informed consent, all three patients received fludarabine 100 mg/m2 on days -6 to -3, cyclophosphamide 60 mg/kg on days -3 and -2, and rabbit anti-thymocyte 16 globulin (r-ATG) 10 mg/kg on days -5 to -2” It should be read as : Following informed consent, all three patients received fludarabine 25 mg/m2 on days -6 to -2 (total dose 125 mg/m2), cyclophosphamide 60 mg/kg on days -3 and -2 (total dose 120 mg/kg) and rabbit anti-thymocyte globulin (r-ATG) 2.5 mg/kg on days -5 to -2 (total dose 10 mg/kg). The original article has been corrected.